Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Draft Framework, Health IT Legislation Still Needed, Senators Say

This article was originally published in The Gray Sheet

Executive Summary

FDA joined two other agencies last week in issuing a proposed new health information technology regulatory framework that would include risk-based oversight and only patient role for FDA. While Senators sponsoring health IT legislation to restrict FDA’s role praised some aspects of the report, they insisted their bill was still necessary. Meanwhile, Device trade groups, in balance, were positive about the propose framework.

You may also be interested in...



Health IT Deregulation Bill Introduced In Senate, With Powerful Industry Backers

The PROTECT Act, which attempts to respond to some criticisms of the House SOFTWARE Act, aims to restrict FDA’s oversight of health information technology. It is backed by IBM and Verizon, among others.

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

Topics

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel